Skip to main content
Authored Items
Association Between Formulary Coverage and Use of Abuse-Deterrent Prescription Opioids, Risk for Abuse or Overdose, and Associated Healthcare Resource Utilization
Allison Petrilla, MPH, Atheer A. Kaddis, PharmD, Elizabeth Marrett, MPH, Xian Shen, PhD, MS, BS, Winghan Jacqueline Kwong, PharmD, PhD, Edmund Pezalla, MD, MPH
February 2020 Vol 13, No 1 in Business, Original Research
Rate of Adverse Events and Healthcare Costs Associated with the Topical Treatment of Rosacea
Todd Williamson, PhD, MSc, Atheer A. Kaddis, PharmD, Rajesh Kamalakar, MS, Augustina Ogbonnaya, MPH, Erin A. Zagadailov, PharmD, MS, Michael Eaddy, PharmD, PhD, Charlie Kreilick, MBA
May 2017 Vol 10, No 3 in Clinical, Original Research
Effects of Specialty Pharmacy Care on Health Outcomes in Multiple Sclerosis
Jun Tang, PhD, Atheer A. Kaddis, PharmD, James Bailey, MD, MPH, Cyril Chang, PhD, Richard Faris, PhD, Song Hee Hong, PhD, Michael Levin, MD, Junling Wang, PhD
November 2016 Vol 9, No 8 in Business
Patient Characteristics and Prescribing Patterns Associated with Sofosbuvir Treatment for Chronic HCV Infection in a Commercially Insured Population
Atheer A. Kaddis, PharmD, Brent M. Tambourine, PharmD, BCPS, Arash Sadeghi, PharmD, Jianing Yang, MD, MS, Karen M. Stockl, PharmD, Heidi C. Lew, PharmD, Brian K. Solow, MD, FAAFP, Josephine N. Tran, PharmD, MS
April 2016 Vol 9, No 2 in Clinical
Why Is My Patient Still in Pain?
Atheer A. Kaddis, PharmD
Faculty Perspectives in Chronic Pain:Utilizing Pharmacogenomics When Selecting Personalized Medicine for Patients with Chronic Pain in Faculty Perspectives
Are We Winning the War on Drugs?
Atheer A. Kaddis, PharmD
Faculty Perspectives in Chronic Pain: Epidemiologic Assessments of Abuse-Deterrent Formulations
The Tip of the Iceberg
Atheer A. Kaddis, PharmD
Faculty Perspectives in Chronic Pain: In Vitro and Clinical Assessments of Abuse-Deterrent Formulations for Chronic Pain
The Value of Pharmaceuticals and Adherence to Therapy in the Management of Hematologic Cancers
Atheer A. Kaddis, PharmD
February 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology in Payers' Perspectives
Budgetary Impact of Adding Riociguat to a US Health Plan for the Treatment of Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension
Atheer A. Kaddis, PharmD, Chakkarin Burudpakdee, PharmD, Anshul Shah, BS Pharm, MS, Vijay N Joish, PhD, Christine H. Divers, PhD, Avin Yaldo, PhD
December 2014 Vol 7, No 9 in Business
The Impact of 5-HT3RA Use on Cost and Utilization in Patients with Chemotherapy- Induced Nausea and Vomiting: Systematic Review of the Literature
Michael S. Broder, MD, MSHS, Atheer A. Kaddis, PharmD, Claudio Faria, PharmD, MPH, Annette Powers, PharmD, MBA, Jehangeer Sunderji, MD, Dasha Cherepanov, PhD
May 2014 Vol 7, No 3 in Business
Infliximab Dosing Patterns in a Sample of Patients with Crohn’s Disease: Results from a Medical Chart Review
Joseph Tkacz, MS, Atheer A. Kaddis, PharmD, Jennifer H. Lofland, PharmD, MPH, PhD, Julie Vanderpoel, PharmD, MPA, Charles Ruetsch, PhD
April 2014 Vol 7, No 2 in Clinical
Resource Utilization and Cost in a Commercially Insured Population with Schizophrenia
Kathryn Fitch, RN, MEd, Atheer A. Kaddis, PharmD, Kosuke Iwasaki, FIAJ, MAAA, Kathleen F. Villa, MS
January/February 2014 Vol 7, No 1 in Business
Insurance Companies’ Perspectives on the Orphan Drug Pipeline
Robert Handfield, PhD, Atheer A. Kaddis, PharmD, Josh Feldstein, BA
November/December 2013, Vol 6, No 9 in Business
Real-World Corticosteroid Utilization Patterns in Patients with Metastatic Castration-Resistant Prostate Cancer in 2 Large US Administrative Claims Databases
Marie-Hélène Lafeuille, MA, Atheer A. Kaddis, PharmD, Jonathan Gravel, MSc, Amanda Grittner, MA, Patrick Lefebvre, MA, Lorie A. Ellis, PhD, Scott McKenzie, MD
July/August 2013 Vol 6, No 6 in Business
Trends in the 2013 Pharmaceutical Pipeline
Dalia Buffery, MA, ABD, Atheer A. Kaddis, PharmD
April 2013 Vol 6 No 3 Payers’ Guide to New FDA Approvals in FDA Approvals, Drug Updates, Payers' Guide
New Directions in the Treatment of Multiple Myeloma: Reports on Carfilzomib-Based Therapy from ASH 2012
Lynne Lederman, PhD, R. Donald Harvey, PharmD, FCCP, BCOP, Beth Faiman, PhD(c), MSN, APRN-BC, AOCN, Atheer A. Kaddis, PharmD
Supplements
Benefits of Novel Oral Anticoagulant Agents for Thromboprophylaxis after Total Hip or Knee Arthroplasty
Richard J. Friedman, MD, FRCSC, Atheer A. Kaddis, PharmD
March/April 2012, Vol 5, No 2 in Clinical
Beyond the Cost of Biologics: Employer Survey Reveals Gap in Understanding Role of Specialty Pharmacy and Benefit Design
F. Randy Vogenberg, PhD, FASHP, Atheer A. Kaddis, PharmD, Cheryl Larson, Margaret Rehayem, MA, Larry Boress, MPA
January/February 2012, Vol 5, No 1 in Business
Atypical Antipsychotics and Metabolic Syndrome in Patients with Schizophrenia: Risk Factors, Monitoring, and Healthcare Implications
Henry J. Riordan, PhD, Atheer A. Kaddis, PharmD, Paola Antonini, MD, PhD, Michael F. Murphy, MD, PhD
September 2011, Vol 4, No 5 in Clinical
Strategies to Prevent Opioid Misuse, Abuse, and Diversion That May Also Reduce the Associated Costs
Atheer A. Kaddis, PharmD, Kathryn L. Hahn, PharmD, DAAPM, CPE
March/April 2011, Vol 4, No 2 in Clinical, Drug Updates
Comparing Medical Cost of Care for Patients with Metastatic Breast Cancer Receiving Taxane Therapy: Claims Analysis
Rex W. Force, PharmD, Atheer A. Kaddis, PharmD, Brooke A. Pugmire, PharmD, Vaughn L. Culbertson, PharmD
July/August 2010, Vol 3, No 4 in Business
Last modified: March 27, 2020